KR101697246B1 - Composition for abirritating tooth-whitening product and kit containing the composition - Google Patents
Composition for abirritating tooth-whitening product and kit containing the composition Download PDFInfo
- Publication number
- KR101697246B1 KR101697246B1 KR1020130141505A KR20130141505A KR101697246B1 KR 101697246 B1 KR101697246 B1 KR 101697246B1 KR 1020130141505 A KR1020130141505 A KR 1020130141505A KR 20130141505 A KR20130141505 A KR 20130141505A KR 101697246 B1 KR101697246 B1 KR 101697246B1
- Authority
- KR
- South Korea
- Prior art keywords
- tooth whitening
- composition
- agent
- irritation
- manganese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000002087 whitening effect Effects 0.000 claims abstract description 83
- 230000007794 irritation Effects 0.000 claims abstract description 34
- 230000000116 mitigating effect Effects 0.000 claims abstract description 11
- 208000003265 stomatitis Diseases 0.000 claims abstract 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 22
- 150000002978 peroxides Chemical class 0.000 claims description 11
- 229960003080 taurine Drugs 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 6
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 6
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 229940048086 sodium pyrophosphate Drugs 0.000 claims description 4
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 4
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 claims description 3
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 claims description 3
- 239000004343 Calcium peroxide Substances 0.000 claims description 3
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 3
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 3
- 235000019402 calcium peroxide Nutrition 0.000 claims description 3
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000001755 magnesium gluconate Substances 0.000 claims description 3
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 3
- 229960003035 magnesium gluconate Drugs 0.000 claims description 3
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 3
- 239000011565 manganese chloride Substances 0.000 claims description 3
- 235000002867 manganese chloride Nutrition 0.000 claims description 3
- 229940099607 manganese chloride Drugs 0.000 claims description 3
- 239000011564 manganese citrate Substances 0.000 claims description 3
- 235000014872 manganese citrate Nutrition 0.000 claims description 3
- 229940097206 manganese citrate Drugs 0.000 claims description 3
- 239000011683 manganese gluconate Substances 0.000 claims description 3
- 235000014012 manganese gluconate Nutrition 0.000 claims description 3
- 229940072543 manganese gluconate Drugs 0.000 claims description 3
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 2
- 239000007844 bleaching agent Substances 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 claims description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 2
- CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical compound [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 claims 2
- 229940099596 manganese sulfate Drugs 0.000 claims 2
- 239000011702 manganese sulphate Substances 0.000 claims 2
- 235000007079 manganese sulphate Nutrition 0.000 claims 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 11
- 239000012190 activator Substances 0.000 abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 10
- 206010040880 Skin irritation Diseases 0.000 description 10
- 231100000475 skin irritation Toxicity 0.000 description 10
- 230000036556 skin irritation Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 6
- 229940069328 povidone Drugs 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- -1 hydrogen ions Chemical class 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940078916 carbamide peroxide Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 235000019830 sodium polyphosphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 2
- 229960001661 ursodiol Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- BPSYZMLXRKCSJY-UHFFFAOYSA-N 1,3,2-dioxaphosphepan-2-ium 2-oxide Chemical compound O=[P+]1OCCCCO1 BPSYZMLXRKCSJY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FDGBQHCDMSYZRC-UHFFFAOYSA-N 2-hydroxy-2-oxo-1,3,2$l^{5}-dioxaphosphinan-4-amine Chemical compound NC1CCOP(O)(=O)O1 FDGBQHCDMSYZRC-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004349 Polyvinylpyrrolidone-vinyl acetate copolymer Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000002170 dentin sensitivity Diseases 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000019448 polyvinylpyrrolidone-vinyl acetate copolymer Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- DQZXOIPVJBKPAK-UHFFFAOYSA-L potassium;sodium;phosphono phosphate Chemical compound [Na+].[K+].OP(O)(=O)OP([O-])([O-])=O DQZXOIPVJBKPAK-UHFFFAOYSA-L 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000036347 tooth sensitivity Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 치아 미백 조성물 또는 치아 미백 패치의 자극을 줄일 수 있는 구강 자극 완화 성분을 함유하는, 치아 미백 조성물 또는 패치의 적용 전에 적용하는 조성물에 관한 것이다. 본 발명은 또한 구강 자극이 완화된 치아 미백용 키트에 관한 것이다. 본 발명의 치아 미백 조성물 또는 패치의 적용 전에 적용하는 조성물은 치아 미백 성분 활성제에 의한 치아 미백 성분의 급격한 활성으로 야기되는 구강 내 자극을 경감시켜 통증을 완화하면서 우수한 치아 미백 효과를 제공한다.The present invention relates to a tooth whitening composition or composition applied prior to application of a tooth whitening composition or patch containing an oral irritation mitigating component capable of reducing the irritation of a tooth whitening patch. The present invention also relates to a tooth whitening kit in which mouth irritation is alleviated. The composition applied before application of the teeth whitening composition or patch of the present invention alleviates the intraoral irritation caused by the rapid activity of the tooth whitening component by the tooth whitening component activator, thereby providing an excellent tooth whitening effect while relieving pain.
Description
본 발명은 치아 미백 제품의 자극을 완화할 수 있는 조성물 및 이러한 조성물과 치아 미백 제품을 포함하는 치아 미백용 키트에 관한 것으로, 더욱 상세하게는 미백 효과가 우수하면서도 미백 성분 활성제에 의한 급격한 구강 내 자극이 경감된 치아 미백 효과를 제공할 수 있는 수단에 관한 것이다.The present invention relates to a composition capable of alleviating irritation of a tooth whitening product, and a tooth whitening kit comprising such a composition and a tooth whitening product. More particularly, the present invention relates to a tooth whitening kit comprising a rapid whitening agent And to a means for providing this reduced tooth whitening effect.
최근 들어 미에 대한 대중의 관심이 증가하면서 치아 미백에 대한 대중의 관심이 증가하고 있다. 치아 미백을 위한 선택으로 치약, 마우스린스 (mouthrinse), 츄잉 껌, 실내 미백, 및 가장 일반적인 상점 또는 치과의사로부터 구입되는 트레이(tray)를 사용한 치아 미백 용액을 포함한다. 치아 미백 용액은 통상적으로 과산화수소와 같은, 치아를 표백하는 활성 성분을 함유한다.In recent years, public interest in teeth whitening has increased as public interest in the beauty has increased. Choices for tooth whitening include toothpaste, mouthrinse, chewing gum, indoor whitening, and tooth whitening solutions using trays purchased from the most common shops or dentists. The tooth whitening solution typically contains an active ingredient that bleaches teeth, such as hydrogen peroxide.
과산화수소는 물, 에탄올, 에테르에 잘 녹으며 수용액에서 수소이온이 일부 해리되어 약한 산성을 띤다. 이러한 과산화수소는 불안정한 물질로, 시간이 경과하면 활성이 계속 낮아지게 된다. 따라서 통상적인 치아 미백 제품은 유통과정에서 과산화수소의 활성이 떨어지는 것을 방지하기 위하여 과산화수소 안정화제를 이용해 활성을 유지하고 있다. Hydrogen peroxide dissolves well in water, ethanol, and ether, and some hydrogen ions dissociate from the aqueous solution, resulting in weak acidity. This hydrogen peroxide is an unstable substance, and its activity is continuously lowered over time. Thus, a typical tooth whitening product maintains its activity by using a hydrogen peroxide stabilizer to prevent the hydrogen peroxide activity from deteriorating during the distribution process.
그러나 실제 치아 미백제 사용 시 이러한 안정화제가 과산화수소의 활성을 나타내지 못하도록 하는 장애 요인으로 작용하는데, 이를 해결하기 위해 촉매를 이용하여 과산화수소의 신속한 활성을 유도하고 있다. However, when the actual tooth whitening agent is used, such a stabilizer acts as an obstacle for preventing the activity of hydrogen peroxide. In order to solve this problem, the hydrogen peroxide is rapidly activated by using a catalyst.
한편 잇몸에 갑작스럽게 과산화물 성분이 닿을 경우 치아 과민성(tooth sensitivity)과 잇몸 자극(gingival irritation) 등을 일으킬 수 있는데, 앞서 언급한 과산화물(예를 들어, 과산화수소)의 신속한 활성을 유도하기 위한 미백 성분 활성화제의 급격한 작용으로 이러한 잇몸 자극 등이 종종 유발되곤 하였다. On the other hand, when the gum is abruptly exposed to peroxide, it may cause tooth sensitivity and gingival irritation. In order to induce rapid activation of the above-mentioned peroxide (for example, hydrogen peroxide) These gum stimulations are often caused by the sudden action of the agent.
따라서, 유통 과정 중에 과산화물의 안정성을 유지하면서도, 과산화물의 충분한 치아 미백 효과를 누릴 수 있고, 이와 동시에 잇몸 등에 전달되는 자극을 최소화하기 위한 해결책이 요구된다.Therefore, there is a need for a solution for minimizing irritation to the gums and the like, while maintaining the stability of the peroxide during the distribution process, while enjoying a sufficient tooth whitening effect of the peroxide.
따라서 본 발명은 위와 같은 문제점을 해결하고자 치아 미백 제품의 치아 및 잇몸 자극을 경감시킬 수 있는 치아 미백 제품의 자극 완화용 조성물을 제공하고자 한다. Accordingly, it is an object of the present invention to provide a composition for relieving irritation of a tooth whitening product that can alleviate tooth and gum irritation of a tooth whitening product in order to solve the above problems.
더 나아가 본 발명은 치아 미백 효과가 우수하면서도 잇몸에 덜 자극적인 치아 미백용 키트를 제공하고자 한다. Furthermore, the present invention provides a tooth whitening kit which is excellent in teeth whitening effect but less irritating to the gum.
또한 본 발명은 우수한 치아 미백 효과를 가지면서 잇몸 자극이 경감된 치아 미백 방법을 제공하고자 한다.The present invention also provides a tooth whitening method having an excellent tooth whitening effect while reducing gum irritation.
상기 과제를 해결하기 위하여, 본 발명은 구강 자극 완화 성분을 함유하는 치아 미백용 키트, 바람직하게는 치아 미백 성분 중, 특히 과산화물의 활성화로 인한 잇몸 자극 등을 완화시켜주면서 치아 미백 효과가 우수한 치아 미백용 키트를 제공한다.In order to solve the above problems, the present invention provides a tooth whitening kit comprising an oral irritation-mitigating component, preferably a tooth whitening component that is effective in relieving gum irritation due to activation of peroxides, For example.
본 발명에 따른 치아 미백용 키트는 구강 자극 완화 성분을, 바람직하게는 구강 자극 완화 성분 및 치아 미백 성분 활성제를 함유하는 제 1제; 및 치아 미백 성분을 함유하는 제 2제를 포함한다. A tooth whitening kit according to the present invention comprises a first agent containing an oral irritation mitigating component, preferably an oral irritation alleviating component and a tooth whitening component activator; And a second agent containing a tooth whitening component.
본 명세서에서 사용된 구강 자극이라 함은 치아 미백 성분 중 특히 과산화물이 활성화됨으로 인해 발생할 수 있는 치아와 잇몸 등에 나타나는 부어오름, 붉어지는 현상, 통증 등을 포함하는 일체의 자극 현상 등을 포함한다.As used herein, oral stimulation includes all irritation phenomena including swelling, redness, pain, etc. appearing on teeth and gums, which may occur due to activation of peroxides, among the whitening ingredients.
또한 완화라 함은 상기와 같은 구강 자극 등이 줄어들거나 누그러지는 것을 의미하며, 개선, 예방, 치료 등을 포함하는 넓은 개념으로 이해될 수 있다. Also, relaxation means that the oral stimulation or the like is reduced or relieved as described above, and can be understood as a broad concept including improvement, prevention, and treatment.
본 발명에 따른 치아 미백 성분은 과산화 수소(hydrogen peroxide), 과산화 요소(carbamide peroxide), 과산화 칼슘(calcium peroxide), 과산화피로인산나트륨(tetrasodium pyrophosphate peroxidate), 중조, 염소계표백제 중에서 선택된 1 종 이상을 포함할 수 있으며, 바람직하게는 과산화 수소(hydrogen peroxide), 과산화 요소(carbamide peroxide), 과산화 칼슘(calcium peroxide), 및 과산화피로인산나트륨(tetrasodium pyrophosphate peroxidate) 중에서 선택된 1 종 이상일 수 있으며, 더욱 바람직하게는 과산화수소 또는 과산화 요소를 포함할 수 있다.The tooth whitening component according to the present invention includes at least one selected from hydrogen peroxide, carbamide peroxide, calcium peroxide, tetrasodium pyrophosphate peroxidate, sodium hypochlorite and chlorine bleach And may be one or more selected from among hydrogen peroxide, carbamide peroxide, calcium peroxide, and tetrasodium pyrophosphate peroxidate, and more preferably, Hydrogen peroxide or a peroxide element.
상기 치아 미백 성분은 제 2제 총 중량 대비 0.01중량% 내지 50중량%를, 바람직하게는 1 중량% 내지 30 중량%포함할 수 있으며, 가장 바람직하게 2.5중량% 내지 20중량%포함될 수 있다.The tooth whitening component may include 0.01 wt% to 50 wt%, preferably 1 wt% to 30 wt%, and most preferably 2.5 wt% to 20 wt% of the total weight of the second agent.
상기 치아 미백 성분들은 유통 시 활성이 낮아지는 것을 방지하기 위하여 추가로 안정화제와 혼합될 수 있다. The tooth whitening ingredients may be further mixed with a stabilizing agent to prevent lowering activity during circulation.
상기 안정화제로는 피로인산나트륨, 산성 피로인산나트륨, 메타인산나트륨, 폴리인산나트륨, 피로인산나트륨칼륨, 피로인산칼륨, 울트라메타인산염, 산성폴리인산나트륨, 에틸렌디아민테트라아세테이트, 아미노트리메틸렌포스페이트 및 이의 염, 하이드록시에틸렌디포스포네이트 및 이의 염, 에틸렌디아민테트라메틸렌포스포네이트 및 이의 염, 디에틸렌트리아민펜타메틸렌포스포네이트 및 이의 염, 알킬 아릴 설포네이트, 알킬 설포네이트 염, 알킬 카르복실레이트 염, 알킬 디페닐 옥사이드 디설포네이트, 스판20(Span 20, Sorbitan Monolaurate), 스판 40(Span 40, Sorbitan Monopalmitate), 스판 60(Span 60, Sorbitan Mono stearate), 스판 80(Span 80; Sorbitan Monooleate), 스판 85(Span 85, Sorbitan Trioleate), 트윈(Tween, POE sorbitan fatty acid ester) 계 및 이들의 혼합물로 이루어진 군에서 선택된 1 종 이상을 포함할 수 있다.Examples of the stabilizer include sodium pyrophosphate, sodium pyrophosphate, sodium metaphosphate, sodium polyphosphate, potassium sodium pyrophosphate, potassium pyrophosphate, ultrametaphosphate, acidic sodium polyphosphate, ethylenediamine tetraacetate, aminotrimethylene phosphate, Salts thereof, hydroxyethylenepolyphosphonates and salts thereof, ethylenediamine tetramethylenephosphonate and salts thereof, diethylenetriaminepenta methylenephosphonate and salts thereof, alkylarylsulfonates, alkylsulfonate salts, alkylcarboxylates Span 20, Sorbitan Monoalate, Span 40, Sorbitan Monopalmitate, Span 60, Sorbitan Mono stearate, Span 80, Sorbitan Monooleate, , Span 85 (Sorbitan Trioleate), Tween (POE sorbitan fatty acid ester), and mixtures thereof. Or more species.
치아 미백 성분 활성제는 치아 미백 성분의 활성을 촉진시키는 작용을 할 수 있으며, 제품 유통 시 미백 성분의 안정화를 위해 사용된 상기 안정화제에 의해 치아에 미백 활성이 저해되는 것을 방지하고 우수한 미백 효과를 유도하기 위하여 사용될 수 있다. The whitening component active agent can act to accelerate the activity of the tooth whitening component and prevent the whitening activity of the teeth from being inhibited by the stabilizing agent used for stabilizing the whitening component during the product distribution, .
상기 치아 미백 성분 활성제는 업계에서 일반적으로 이용되고 있는 과산화물의 활성화를 위한 성분들이 이용될 수 있고, 이들에 특별히 한정되지 않는다. 다만, 바람직하게는 2가 또는 3가 금속촉매, pH 조절제 또는 이들의 혼합물을 포함할 수 있다. As the tooth whitening component activator, components for activating peroxides generally used in the industry can be used, and they are not particularly limited thereto. However, preferably a divalent or trivalent metal catalyst, a pH adjusting agent or a mixture thereof may be included.
상기 2가 또는 3가 금속촉매는 과산화물의 분해를 촉진시킬 수 있다. 상기 2가 또는 3가 금속촉매는 바람직하게는 칼슘, 마그네슘, 망간, 구리, 철 또는 칼륨 이온을 방출할 수 있으며, 더욱 바람직하게는 염화마그네슘, 글루콘산마그네슘, 젖산철, 글루콘산철 염화철, 황산망간, 글루콘산망간, 염화망간 및 구연산망간 등이 이용될 수 있다. The bivalent or trivalent metal catalyst can promote decomposition of the peroxide. The bivalent or trivalent metal catalyst is preferably capable of releasing calcium, magnesium, manganese, copper, iron or potassium ions, more preferably magnesium chloride, magnesium gluconate, iron lactate, ferrous gluconate, Manganese, manganese gluconate, manganese chloride and manganese citrate may be used.
상기 pH 조절제는 과산화물과 반응하여 퍼하이드록시라디칼을 발생시켜 치아미백효과를 증진시킬 수 있으며, 이러한 알칼리 pH조절제로는 수산화나트륨, 수산화칼륨, 인산나트륨, 인산이나트륨, 인산삼나트륨, 피로인산나트륨, 구연산나트륨, EDTA-4Na으로 이루어진 군으로부터 선택된 1종 이상의 것을 사용할 수 있으나, 이에 한정하는 것은 아니다. 이러한 알칼리 pH조절제는 조성물의 pH가 8~11이 되도록 적량을 사용할 수 있다. The pH adjusting agent may react with peroxides to generate perhydroxy radicals to enhance the tooth whitening effect. Examples of the alkaline pH adjusting agent include sodium hydroxide, potassium hydroxide, sodium phosphate, disodium phosphate, sodium phosphate, sodium pyrophosphate , Sodium citrate, and EDTA-4Na may be used, but the present invention is not limited thereto. Such an alkaline pH adjusting agent may be used in an appropriate amount so that the pH of the composition is from 8 to 11. [
상기 치아 미백 성분들을 포함하는 치아 미백제 사용 시 안정화제가 미백 성분이 활성을 나타내지 못하도록 하는 장애요인으로 작용하는데, 이를 해결하기 위해 상기 언급한 치아 미백 성분 활성제를 이용하게 된다. 이 때 갑작스런 미백 성분의 활성으로 인해 구강 내에 자극감을 유발하고, 특히 잇몸 자극 및 손상을 유발하는 원인이 된다. When the tooth whitening agent containing the tooth whitening components is used, the stabilizing agent acts as an obstacle which prevents the whitening component from exhibiting activity. To solve this problem, the above-mentioned tooth whitening component activator is used. At this time, the sudden whitening activity causes the irritation in the oral cavity, which causes the irritation and damage of the gums in particular.
본 발명의 키트 중 제 1제는 상기와 같은 구강 내 자극을 완화하면서 우수한 미백 작용을 하기 위해 메티오닌, 시스테인 및 타우린을 포함하는 아미노산; 우르소데옥시콜린산(ursodeoxycholic acid) 및 타우로우르소데옥시콜린산(tauroursodeoxycholic acid)을 포함하는 유기산; 그리고 비타민 A, C, 및 E를 포함하는 비타민으로 이루어진 군에서 선택된 1 종 이상인 구강 자극 완화 성분을 포함할 수 있으며, 바람직하게는 메티오닌, 시스테인 및 타우린을 포함하는 아미노산, 더욱 바람직하게는 타우린이 사용된다.The first of the kits of the present invention comprises an amino acid including methionine, cysteine, and taurine in order to exert an excellent whitening action while alleviating the intraoral irritation as described above; Organic acids including ursodeoxycholic acid and tauroursodeoxycholic acid; And vitamins including vitamins A, C, and E, and preferably an amino acid including methionine, cysteine, and taurine, more preferably taurine is used. do.
상기 구강 자극 완화 성분은 제 1제, 제 2제 또는 제 1제와 제 2제 모두에 포함될 수 있으나, 바람직하게는 제 1제에 포함되어 사용될 수 있다. The oral irritation mitigation component may be included in the first agent, the second agent, or both the first agent and the second agent, but may be preferably included in the first agent.
미백 성분 활성제와 함께 치아 표면에 도포된 후 상기 치아 미백 성분이 함유된 제 2제가 도포될 때 자극 완화 효과가 가장 우수하게 나타날 것으로 생각되기 때문이다. This is because when the second agent containing the tooth whitening component is applied to the tooth surface together with the whitening component activator, the stimulation relaxation effect will be most excellent.
본 발명에 따른 상기 구강 자극 완화 성분은 상기 제 1제 총 중량 대비 0.001 내지 10 중량% 포함될 수 있으며, 바람직하게는 0.01 내지 5 중량%, 더욱 바람직하게는 0.05 내지 3 중량% 포함될 수 있다. The oral irritation mitigation ingredient according to the present invention may be contained in an amount of 0.001 to 10% by weight, preferably 0.01 to 5% by weight, more preferably 0.05 to 3% by weight based on the total weight of the first agent.
상기 구강 자극 완화 성분의 함량이 0.001 중량% 미만일 경우, 자극 완화에 대한 적절한 효과를 기대하기 어려울 수 있으며, 함량이 10 중량% 초과하는 경우, 과산화수소에 의한 미백효과에 영향을 미쳐 본 발명의 전체적인 미백 효과를 저하시킬 수 있다. If the content of the oral irritation mitigating component is less than 0.001% by weight, it may be difficult to expect an appropriate effect on stimulation relaxation. If the content exceeds 10% by weight, the whitening effect by hydrogen peroxide may be affected, The effect may be deteriorated.
본 발명의 치아 미백용 키트에 포함되는 제 1제는 자체적인 점도에 의해서 치아에 부착 가능한 젤(gel) 상태가 바람직하나, 건조 상태로서도 사용 가능하다. The first agent contained in the tooth whitening kit of the present invention is preferably in a gel state capable of being adhered to teeth by its own viscosity, but it can also be used as a dry state.
여기에 사용 가능한 고분자는 폴리 알킬 비닐 에테르-말레인산 공중합체(PVM/MA copolymer, Gantrez AN 119, AN 139, S-97), 폴리 비닐 알코올, 폴리 아크릴 산, Poloxamer (poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer), 폴리 에틸렌 옥사이드(Polyox), 폴리 비닐 피롤리돈-비닐 아세테이트 공중합체(PVP/VA copolymer; Luviskol VA, Plasdone S PVP/VA), 폴리 비닐 피롤리돈(PVP, K15 ~ K-120), Polyquaterium-11(Gafquat 755N), Polyquaterium-39(Merquat plus 3330), 카르복시 폴리 메틸렌(Carbopol), 하이드록시 프로필 메틸 셀룰로오즈, 하이드록시 에틸 셀룰로오즈, 하이드록시 프로필 셀룰로오즈, 젤라틴(Gelatin), 알긴 산(Sodium Alginate) 또는 이들의 혼합물 중에서 선택할 수 있다. 이들의 용매로는 주로 물, 에탄올 단독 또는 이들의 혼합물, 그리고 다른 유기 용매들 예를 들면 에틸 아세테이트, 메틸렌 클로라이드, 이소프로필 알코올, 아세토 나이트릴 단독이나 이들의 혼합물을 비율을 조절하여 사용할 수도 있다.Polymers usable herein include polyalkyl vinyl ether-maleic acid copolymers (PVM / MA copolymer, Gantrez AN 119, AN 139, S-97), polyvinyl alcohol, polyacrylic acid, polyoxamer polyvinylpyrrolidone-vinyl acetate copolymer (PVV / VA copolymer: Luviskol VA, Plasdone S PVP / VA), polyvinylpyrrolidone (PVP, K15 to K-120), Polyquaterium-11 (Gafquat 755N), Polyquaterium-39 (Merquat plus 3330), Carbopol, Carbopol, hydroxypropylmethyl cellulose, , Gelatin, Sodium Alginate, or a mixture thereof. These solvents may be mainly water, ethanol alone or a mixture thereof, and other organic solvents such as ethyl acetate, methylene chloride, isopropyl alcohol, acetonitrile alone or a mixture thereof.
상기 제 2제는 치아 미백 성분이 함유되어 있으며, 제품의 형태를 유지하고 유효성분을 보호해주는 역할을 할 수 있다. 본 발명의 제 2제는 치아 표면에 부착이 가능한 패치의 형태로 제작될 수 있다. 본 발명에 따른 치아 부착용 패치는, 예를 들어, 미국특허 제6,682,721호, 제6,689,344호, 제6,780,401호, 제6,946,142호 등에 개시된 방법으로 제조될 수 있으나, 본 발명은 이러한 패치의 구성 성분과 제조 방법에 한정되는 것은 아니다.The second agent contains a tooth whitening component and can maintain the shape of the product and protect the active ingredient. The second agent of the present invention can be produced in the form of a patch capable of adhering to a tooth surface. The patch for dental attachment according to the present invention can be produced by, for example, the methods disclosed in U.S. Patent Nos. 6,682,721, 6,689,344, 6,780,401, 6,946,142, etc., .
본 발명의 또 다른 실시예들에 따르면, 본 발명은 치아 미백 제품의 구강 자극을 완화하기 위한 유효 성분으로 메티오닌, 시스테인 및 타우린을 포함하는 아미노산; 우르소데옥시콜린산(ursodeoxycholic acid) 및 타우로우르소데옥시콜린산(tauroursodeoxycholic acid)을 포함하는 유기산; 및 비타민 A, C 및 E를 포함하는 비타민으로 이루어진 군에서 선택된 1 종 이상을 포함하는 치아 미백 제품의 구강 자극을 완화하는 조성물을 제공한다. According to another embodiment of the present invention, there is provided a tooth whitening product comprising an amino acid comprising methionine, cysteine and taurine as an effective ingredient for alleviating oral stimulation of a tooth whitening product; Organic acids including ursodeoxycholic acid and tauroursodeoxycholic acid; And vitamins including vitamins A, C, and E. The present invention provides a composition for relieving oral stimulation of a tooth whitening product.
상기 조성물은 치아 미백 성분 활성제를 추가로 포함할 수 있다. The composition may further comprise a tooth whitening component active agent.
상기 구강 자극 완화를 위한 조성물은 치아 미백 제품의 적용 전에 사용되는데, 이는 치아 미백 성분 활성제에 의한 치아 미백 성분의 급격한 활성으로 야기되는 구강 내 자극을 경감시키거나, 통증을 완화하기 위해서이다.The composition for alleviating oral irritation is used before application of a tooth whitening product in order to alleviate pain or relieve oral irritation caused by the rapid activation of a tooth whitening ingredient by a tooth whitening component activator.
상기 구강 자극 완화성분은 상기 조성물 총 중량 대비 0.01 내지 10 중량% 포함될 수 있으며, 바람직하게는 0.1 내지 5 중량%, 더욱 바람직하게는 0.15 내지 3 중량% 포함될 수 있다.The oral irritation mitigation ingredient may be included in an amount of 0.01 to 10% by weight, preferably 0.1 to 5% by weight, more preferably 0.15 to 3% by weight based on the total weight of the composition.
본 발명은 치아 미백 성분 단독, 또는 치아 미백 성분과 치아 미백 성분 활성제를 함께 사용할 때 발생할 수 있는 구강 내 자극을 완화시킬 수 있는 치아 미백 제품의 자극완화용 조성물, 및 이러한 조성물과 치아 미백 제품을 포함하는 치아 미백용 키트를 제공한다. The present invention relates to a composition for relieving irritation of a tooth whitening product which can alleviate oral irritation which may occur when a tooth whitening component alone or a tooth whitening component and a tooth whitening component activator are used together, and a tooth whitening product And a tooth whitening kit.
본 발명에 따른 자극완화용 조성물 및 치아 미백제는 우수한 치아 미백 효과를 가지면서 구강 내, 특히 잇몸 자극을 최소화할 수 있다.The composition for relieving irritation and the tooth whitening agent according to the present invention have an excellent tooth whitening effect and can minimize irritation in the oral cavity, especially gums.
도 1은 본 발명의 치아 미백용 키트를 이용한 후 치아 명도 변화량을 나타낸 그래프이다.
도 2는 피부 자극도를 나타낸 그래프이다.
도 3은 자극도에 대한 설문 평가 결과를 나타낸 그래프이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing changes in posterior toothiness using a tooth whitening kit of the present invention. FIG.
2 is a graph showing the degree of skin irritation.
3 is a graph showing the result of questionnaire evaluation on the degree of stimulus.
이하, 본 발명을 보다 구체적으로 설명하기 위하여 하기 실시예 등을 들어 설명한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며 본 발명의 범위가 아래에서 상술하는 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 본 발명의 구체적 이해를 돕기 위해 예시적으로 제공되는 것이다.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the above-described embodiments. The embodiments of the present invention are provided by way of example to facilitate a specific understanding of the present invention.
<실시예 및 비교예>≪ Examples and Comparative Examples &
하기 표 1에 나타낸 바와 같은 구성비로 업계에서 통상적인 방법으로 본 발명에 따른 치아 미백 키트를 제조하였다. 하기 표 1의 함량 단위는 중량%이다.The tooth whitening kits according to the present invention were produced in a manner customary in the art with the composition ratios shown in Table 1 below. The content units in the following Table 1 are% by weight.
첨가물질First agent (gelatin)
Additive substance
3.0%Hydrogen peroxide
3.0%
3.0%Hydrogen peroxide
3.0%
3.0%Hydrogen peroxide
3.0%
3.0%Hydrogen peroxide
3.0%
3.0%Hydrogen peroxide
3.0%
시험예Test Example 1. 미백 효과 실험-명도 변화량 1. Whitening effect experiment - Change in brightness
1) 실험 방법1) Experimental method
비교예 2, 실시예1 및 실시예2를 각각 인공 착색된 HAP disk에 부착하고 1시간 경과 후 제거하여 초기 대비 명도 변화량을 측정하였다. Comparative Example 2, Example 1 and Example 2 were attached to an artificially colored HAP disk, respectively, and after 1 hour had elapsed, the initial contrast change was measured.
2) 실험 결과2) Experimental results
그 결과를 도 1에 나타내었다. 도 1에 나타난 바와 같이, 과산화수소만 처방한 비교예 2에 비해서 실시예 1 및 실시예 2는 약 70% 이상 개선된 미백 효과를 나타내는 것을 알 수 있었다.
The results are shown in Fig. As shown in Fig. 1, it can be seen that Example 1 and Example 2 showed a whitening effect improved by about 70% or more as compared with Comparative Example 2 in which only hydrogen peroxide was prescribed.
시험예Test Example 2. 자극성 관련 패치 테스트 2. Irritation Related Patch Test
1) 실험 방법1) Experimental method
팔에 피부질환이 없는 남성 11명을 선정하여 상기 비교예와 실시예를 각각 2.5cm X 2.5cm크기로 도포/부착한 후 1시간 방치한다. 1시간 경과 후 제거하고 남은 겔제를 흐르는 물로 씻어낸 후 30분 뒤 피부 자극도를 하기 판정 기준에 따라 판정하였다.Eleven men with no skin disease on their arms were selected, and the comparative example and the example were applied / attached in a size of 2.5 cm x 2.5 cm, respectively, and left for 1 hour. After 1 hour, the gel was removed, and the remaining gel was washed with running water. After 30 minutes, the skin irritation was judged according to the following criteria.
<판정 기준><Criteria>
(CTFA/ICDRG Guideline, Textbook of contact dermatitis)(CTFA / ICDRG Guideline, Textbook of contact dermatitis)
+/-
+
++
+++-
+/-
+
++
+++
0.5
1.0
2.0
3.00
0.5
1.0
2.0
3.0
약한 홍반
명확한 홍반
부종을 동반한 심한 홍반
수포 및 부종을 동반한 심한 홍반No response
Weak erythema
Clear erythema
Severe erythema with edema
Severe erythema with blistering and edema
2) 실험 결과2) Experimental results
도 2에 나타난 결과에 따르면, 피부 자극도를 판정한 결과 비교예 1 및 비교예 2에 비해서 실시예 2 내지 4에서 피부 자극 현상이 현저히 감소한 것을 알 수 있었다. 특히, 피부 자극 완화 성분 중에서 타우린을 첨가한 실시예 2는 피부 자극도가 가장 낮은 것으로 나타났다.According to the result shown in FIG. 2, skin irritation was significantly reduced in Examples 2 to 4 as compared with Comparative Examples 1 and 2 as a result of judging skin irritation degree. In particular, Example 2 in which taurine was added among the skin irritation mitigating ingredients showed the lowest skin irritancy.
뿐만 아니라, 미백 성분 활성제가 피부 자극 완화 성분과 함께 사용되지 않을 경우 비교예 1 및 2에 비해서 훨씬 더 강한 피부 자극을 유발할 수 있다는 것이 실험을 통하여 입증되었다. In addition, it has been demonstrated through experiments that, when the whitening component active agent is not used with the skin irritation mitigating component, much stronger skin irritation can be induced as compared to Comparative Examples 1 and 2.
따라서 실험예 1 및 2의 결과를 종합해 볼 때, 미백 성분 활성제와 피부 자극 완화 성분을 함께 사용할 때 잇몸 등에 자극이 없으면서 우수한 치아 미백 효과를 얻을 수 있다는 사실을 알 수 있었다.
Therefore, when the results of Experimental Examples 1 and 2 are combined, it can be seen that when a whitening component activator and a skin irritation reducing ingredient are used together, an excellent tooth whitening effect can be obtained without irritation to the gums and the like.
시험예Test Example 3. 자극 관련 설문 평가 3. Evaluation of stimulation related questionnaires
비교예2, 실시예1 및 실시예2를 각각 피험자에게 사용토록 한 뒤 자극도에 대해 3점 척도로 하기 평가 기준에 따라 평가하도록 하였다.The subjects of Comparative Example 2, Example 1 and Example 2 were each allowed to use a three-point scale for the degree of irritation according to the following evaluation criteria.
<평가 기준><Evaluation Criteria>
0 : 자극이 전혀 없음0: No stimulation at all
1 : 미미한 자극이 있음.1: There is slight stimulation.
2 : 확실하게 느껴지는 자극이 있음.2: There is a certain stimulus.
3 : 자극으로 인해 사용 중단
3: Disruption due to stimulation
도 3에 나타난 결과에 따르면, 염화철을 사용할 경우 사용하지 않을 때보다 자극을 심하게 느끼는 것으로 나타났으나, 타우린을 함유한 경우 피부 자극을 느끼는 정도가 훨씬 감소된 것을 알 수 있었다. The results shown in FIG. 3 show that when iron chloride is used, irritation is more severe than when it is not used, but the degree of skin irritation is significantly reduced when taurine is added.
이러한 설문 평가 결과는 실험예 2의 자극성 관련 패치 테스트와 동일하게 타우린 등에 의해 피부 자극이 완화되었음을 보여주었다.The results of the questionnaire evaluation showed that the skin irritation was alleviated by taurine and the like as in the stimulus related patch test of Experimental Example 2.
Claims (14)
과산화 수소, 과산화 요소, 과산화 칼슘, 과산화피로인산나트륨, 중조 및 염소계표백제 중에서 선택되는 1종 이상인 치아 미백 성분을 함유하는 제 2제를 포함하는 치아 미백용 키트.A first agent containing an oral irritation mitigating component which is taurine, tauroursodeoxycholic acid or a mixture thereof; And
A tooth whitening kit comprising a second agent containing at least one tooth whitening component selected from hydrogen peroxide, peroxide element, calcium peroxide, sodium pyrophosphate, sodium hypochlorite and chlorine bleach.
상기 타우린, 타우로우르소데옥시콜린산(tauroursodeoxycholic acid) 또는 이들의 혼합물 및
염화마그네슘, 글루콘산마그네슘, 젖산철, 글루콘산철 염화철, 황산망간, 글루콘산망간, 염화망간, 구연산망간, pH 조절제 또는 이들의 혼합물인 치아 미백 성분 활성제를 포함하는 것을 특징으로 하는 키트.2. The apparatus according to claim 1, wherein the first agent
The above-mentioned taurine, tauroursodeoxycholic acid or a mixture thereof, and
Characterized in that it comprises a tooth whitening component active agent which is magnesium chloride, magnesium gluconate, iron lactate, iron ferric gluconate, manganese sulfate, manganese gluconate, manganese chloride, manganese citrate, pH adjusting agent or a mixture thereof.
타우린, 타우로우르소데옥시콜린산(tauroursodeoxycholic acid) 또는 이들의 혼합물인 구강 자극 완화 성분을 포함하는 것을 특징으로 하는
치아 미백 제품의 구강 자극 완화용 조성물.As an effective ingredient to alleviate mouth irritation in tooth whitening products
Taurine, tauroursodeoxycholic acid, or a mixture thereof. ≪ RTI ID = 0.0 >
A composition for alleviating oral irritation of a tooth whitening product.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130141505A KR101697246B1 (en) | 2013-11-20 | 2013-11-20 | Composition for abirritating tooth-whitening product and kit containing the composition |
| CA2930230A CA2930230C (en) | 2013-11-20 | 2014-11-19 | Oral composition for tooth whitening product, and kit comprising the same |
| US15/037,181 US20160287501A1 (en) | 2013-11-20 | 2014-11-19 | Oral composition for tooth whitening product, and kit comprising same |
| CN201480063492.7A CN105764473B (en) | 2013-11-20 | 2014-11-19 | Oral composition for tooth whitening product and kit comprising the same |
| PCT/KR2014/011135 WO2015076559A1 (en) | 2013-11-20 | 2014-11-19 | Oral composition for tooth whitening product, and kit comprising same |
| US15/332,229 US20170035669A1 (en) | 2013-11-20 | 2016-10-24 | Oral composition for tooth whitening product, and kit comprising same |
| US15/703,384 US10195129B2 (en) | 2013-11-20 | 2017-09-13 | Oral composition for tooth whitening product, and kit comprising same |
| US16/218,925 US20190110972A1 (en) | 2013-11-20 | 2018-12-13 | Oral composition for tooth whitening product, and kit comprising same |
| US16/225,377 US20190125646A1 (en) | 2013-11-20 | 2018-12-19 | Oral composition for tooth whitening product, and kit comprising same |
| US16/405,760 US10758469B2 (en) | 2013-11-20 | 2019-05-07 | Oral composition for tooth whitening product, and kit comprising same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130141505A KR101697246B1 (en) | 2013-11-20 | 2013-11-20 | Composition for abirritating tooth-whitening product and kit containing the composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150057749A KR20150057749A (en) | 2015-05-28 |
| KR101697246B1 true KR101697246B1 (en) | 2017-01-17 |
Family
ID=53392548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130141505A Active KR101697246B1 (en) | 2013-11-20 | 2013-11-20 | Composition for abirritating tooth-whitening product and kit containing the composition |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101697246B1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102395569B1 (en) * | 2015-11-18 | 2022-05-10 | (주)아모레퍼시픽 | Oral composition for tooth whitening |
| KR102732575B1 (en) * | 2021-12-10 | 2024-11-19 | 주식회사 엘지생활건강 | Oral composition for promoting teeth whitening comprising co-precipitate |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004292429A (en) | 2003-03-10 | 2004-10-21 | Gc Corp | Tooth bleach set and tooth bleaching method |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004107231A (en) * | 2002-09-17 | 2004-04-08 | Showa Yakuhin Kako Kk | Oral composition |
| KR20040095898A (en) * | 2003-04-29 | 2004-11-16 | 애경산업(주) | Patch for whitening a teeth |
| KR101154932B1 (en) * | 2005-01-10 | 2012-06-13 | 주식회사 엘지생활건강 | The tooth whitening strip increasing safety |
-
2013
- 2013-11-20 KR KR1020130141505A patent/KR101697246B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004292429A (en) | 2003-03-10 | 2004-10-21 | Gc Corp | Tooth bleach set and tooth bleaching method |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150057749A (en) | 2015-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marshall et al. | Hydrogen peroxide: a review of its use in dentistry | |
| EP0446524B1 (en) | Oral hygiene composition | |
| TWI558418B (en) | Oral care composition | |
| US10195129B2 (en) | Oral composition for tooth whitening product, and kit comprising same | |
| EP3187169B1 (en) | Oral composition for alleviation of dentin hypersensitivity | |
| US20060198799A1 (en) | Tooth glossing or finishing compositions for oral care | |
| EP1066823A1 (en) | Tooth whitening composition | |
| US20130295526A1 (en) | Method and apparatus for applying a protective oral care composition | |
| RU2018144620A (en) | COMPOSITIONS FOR CARE OF THE ORAL CAVITY AND METHODS OF USE | |
| TW201538175A (en) | Oral care compositions and methods | |
| US6645472B1 (en) | Oral hygiene powder composition and method | |
| TWI653986B (en) | Oral health care composition and method | |
| TW201609165A (en) | Oxidizing system for oral care compositions | |
| KR101697246B1 (en) | Composition for abirritating tooth-whitening product and kit containing the composition | |
| KR102395569B1 (en) | Oral composition for tooth whitening | |
| WO1992018095A1 (en) | Antimicrobial oral compositions | |
| KR102187824B1 (en) | Gel composition for adhesiving teeth surface and kit comprising the same | |
| US10758469B2 (en) | Oral composition for tooth whitening product, and kit comprising same | |
| TW201534340A (en) | Oral care compositions and methods | |
| TWI679027B (en) | Oral care compositions and methods | |
| JP2760573B2 (en) | Oral composition for inhibiting plaque adhesion | |
| KR101514014B1 (en) | Multi-part tooth bleaching composition and method of bleaching tooth | |
| TWI568450B (en) | Oral care whitening compositions | |
| KR20150111654A (en) | Composition for improving tooth-whitening effect and kit comprising the same | |
| JPH0338512A (en) | Mouth-washing agent for inhibiting bacterial plaque on teeth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20131120 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160608 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20131120 Comment text: Patent Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20160608 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20131120 Patent event code: PA03021R01I Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160621 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20170108 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20170111 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20170111 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200102 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210107 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220103 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20221226 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20231226 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20241223 Start annual number: 9 End annual number: 9 |